General Information of the Drug (ID: M6APDG03672)
Name
XGP-110
Synonyms
Synoviocyte/tumor cell inhibitor + COX-2 inhibitor (arthritis/cancer/cancer pain), Xaragen
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D0N8TM
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Prostaglandin G/H synthase 2 (COX-2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Prostaglandin G/H synthase 2 (COX-2) is a therapeutic target for XGP-110. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of XGP-110 through regulating the expression of Prostaglandin G/H synthase 2 (COX-2). [1], [2]
References
Ref 1 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376).